Drug Shortage Report for TEVA-NAPROXEN EC
| Report ID | 124986 |
| Drug Identification Number | 02243313 |
| Brand name | TEVA-NAPROXEN EC |
| Common or Proper name | NAPROXEN-EC 375MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | NAPROXEN |
| Strength(s) | 375MG |
| Dosage form(s) | TABLET (ENTERIC-COATED) |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | M01AE |
| ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-09-23 |
| Estimated end date | 2020-11-30 |
| Actual end date | 2020-10-21 |
| Shortage status | Resolved |
| Updated date | 2020-10-22 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2020-10-22 | French | Compare |
| v5 | 2020-10-22 | English | Compare |
| v4 | 2020-10-15 | French | Compare |
| v3 | 2020-10-15 | English | Compare |
| v2 | 2020-09-24 | French | Compare |
| v1 | 2020-09-24 | English | Compare |
Showing 1 to 6 of 6